Adjuvant Therapy In Breast Cancer And Bone Health
Víctor Manuel Vargas-Hernández, Víctor Manuel Vargas Aguilar
Background: breast cancer is the most common tumor in women worldwide and osteoporosis is
linked to it, 70-80% of patients receive adjuvant endocrine therapy to improve prognosis; but, they
accelerate bone loss and increase the risk of fractures by causing inflammation that stimulates bone
breakdown and slows bone growth; Assessment of initial risk of fracture, monitoring of bone health and
individualization based on initial risk, implementation of non-pharmacological measures, consideration
of bone mineral density T-scores, guidance on criteria for starting antiresorptive treatment, choice of
agents and duration of treatment, taking into account the oncological benefits of antiresorptive treatment.
Objective: to analyze and evaluate the causes of bone loss in patients with breast cancer, adequate
detection to estimate the risk of osteoporosis and fractures, prevention and therapeutic strategies for
these, and the role of antiresorptive agents as adjuvant therapy. Conclusions: Despite advances in the
management of bone loss induced by breast cancer, the optimal time to start antiresorptive agents and the
duration of treatment remain unanswered; although, the evidence supports the use of therapeutic agents
to protect bone health in breast cancer. Future clinical trials, as well as increased awareness of bone
health, are needed to improve prevention, evaluation, and treatment in long-term breast cancer survivors.
